alere inc (ALR) Key Developments
Alere Inc. Receives FDA Clearance for Alere i Strep A Rapid Molecular Test
Apr 2 15
Alere Inc. announced that its Alere i Strep A test has received marketing clearance from the U.S. Food and Drug Administration (FDA). Alere i Strep A is the first molecular test that detects Group A Streptococcus (GAS) bacteria in throat swab specimens in 8 minutes or less. Upon receipt of this clearance from the FDA, Alere submitted an application for CLIA (Clinical Laboratory Improvement Amendments) waiver of the Alere i Strep A test. Other assays currently in development on the Alere i platform include respiratory syncytial virus (RSV), C. difficile and Chlamydia/Gonorrhoea. The Alere i molecular platform was initially cleared for marketing by the FDA for the detection and differentiation of influenza A and B virus in June 2014. In January 2015, Alere i Influenza A & B became the first-ever molecular test to receive CLIA waiver, which allows for broad use by healthcare providers, ranging from hospitals and physician offices to clinics and other healthcare settings. Expanding the menu on the Alere i platform to include Strep A and potentially other assays increases the utility of the platform for a wider range of users. Furthermore, given the less seasonal nature of Strep A, its addition enhances the value of the platform for users on a year-round basis.
Alere Inc. Announces Executive Changes
Mar 23 15
Alere Inc. announced that James F. Hinrichs will be appointed Executive Vice President and Chief Financial Officer, effective April 6, 2015, with global responsibility for Finance, Procurement, IT and Shared Services. Hinrichs succeeds David Teitel who will remain with the company during a transition period. Hinrichs joins Alere with nearly 25 years of experience in financial and executive leadership roles across the healthcare industry. He most recently served as the CFO of CareFusion.
Alere Announces Resignation of David Teitel as Chief Financial Officer Transition
Mar 9 15
Alere Inc. announced that David Teitel, the company's Chief Financial Officer (CFO), will transition from the role of Chief Financial Officer when a suitable successor is hired. Mr. Teitel intends to continue in the CFO role until his successor is named and to work closely with the management team, including the new CFO, to facilitate a smooth and successful transition of his responsibilities.
Alere Inc. Declares Cash Dividend on Series B Convertible Perpetual Preferred Stock, Payable on April 15, 2015
Mar 3 15
Alere Inc. has declared a cash dividend of $3.00 per share on its series B convertible perpetual preferred stock. The dividend is payable on April 15, 2015 to holders of record of series B stock at the close of business on April 1, 2015. Such payment will cover the amount of all dividends accrued from January 1, 2015 through March 31, 2015.
Alere Inc. announced delayed annual 10-K filing
Mar 3 15
On 03/03/2015, Alere Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.